Legal Representation
Attorney
J. Christopher Lynch
USPTO Deadlines
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 18, 2011 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Jul 18, 2011 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jan 14, 2011 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 13, 2011 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Dec 15, 2010 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jan 13, 2011 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Dec 15, 2010 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 15, 2010 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 20, 2010 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 20, 2010 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 12, 2010 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Mar 12, 2010 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 10, 2010 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 10, 2010 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 10, 2010 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Feb 16, 2010 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 30, 2009 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 30, 2009 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 30, 2009 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 19, 2009 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 18, 2009 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 18, 2009 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for medical or veterinary purposes, namely, pharmaceutical preparations for the treatment or mediation of injury to humans or animals caused by inappropriate or excessive activation of the innate immune system
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Pharmaceutical drug development services
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
042